The Annual HMNCC GI Oncology Summit - December 5, 2025

Houston, TX US
December 5, 2025

In-Person and Virtual attendance options are available. 

Presented by the Houston Methodist Dr. Mary and Ron Neal Cancer Center

This Summit will delve into the latest developments in managing gastrointestinal  cancers. It will feature expert presentations on advancements in immunotherapy, molecular diagnostics,  targeted therapies and new surgical techniques, . Participants will also explore key trends in transplant oncology and the role of precision medicine. Each session will offer insights into disease pathogenesis, risk factors, prevention strategies, and innovative treatments, including discussions on minimally invasive procedures, enhanced imaging, and blood-based biomarkers. The symposium will emphasize how these advancements improve patient outcomes and provide a comprehensive review of current and emerging management strategies for various gastrointestinal cancers.

FEES

REGISTRATION TYPEFEE
Houston Methodist EmployeesComplimentary
Physician (Private physician located within the Greater Houston Area)*$200
Physician (Private physician located outside the Greater Houston Area)Complimentary
Research Scientist Complimentary
Allied Health Care Professional / All OthersComplimentary
Resident / Fellow / Student Complimentary

* In compliance with HM’s policy on Physician Non-Monetary Compensation regarding “Stark Law,” private physicians who reside and/or practice medicine within the Greater Houston Area are required to pay the full Fair Market Value registration fee.

Presenters, topics, program schedule, and credit is subject to change

Target Audience

This Summit is designed for physician scientists, practicing oncologists, hepatologists, transplant surgeons, physician assistants, advanced nurse practitioners, oncology nurses, gastroenterologists, residents, fellows, medical students, allied health care professionals, and clinical research associates. Attendees involved in hepatobiliary, pancreatic, neuroendocrine, colorectal, esophageal, and gastric cancer care will find valuable insights for advancing their practice and improving patient care.

Learning Objectives

At the conclusion of this activity, the learner should be able to:

  • Describe the epidemiology, risk factors, and prevention strategies for gastrointestinal cancers.
  • Review the pathogenesis, surveillance modalities, and underuse of screening for hepatocellular carcinoma (HCC), focusing on blood-based biomarkers and management of pre-liver cancer diseases.
  • Evaluate transplant-bridging approaches and the role of immunotherapy in both resectable and advanced hepatocellular carcinoma, as well as new developments in treating advanced cholangiocarcinoma.
  • Assess updates on operative strategies for early-stage hepatobiliary cancers and transplant oncology for hilar and intrahepatic cholangiocarcinoma.
  • Explain the latest advancements in molecular diagnostics, operative and perioperative approaches, and targeted therapies for pancreatic adenocarcinoma, low-/intermediate-grade neuroendocrine carcinoma, and colorectal cancers.
  • Discuss advancements in multidisciplinary approaches for managing esophageal and gastric cancers, as well as the role of precision medicine in unresectable gastrointestinal malignancies
Course summary
Available credit: 
  • 5.25 AMA PRA Category 1 Credit™

    Houston Methodist is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Houston Methodist designates this Live activity for a maximum of 5.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 5.25 Nursing Contact Hours

    Houston Methodist is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

    Houston Methodist will award up to 5.25 nursing professional development contact hours for this activity.

Course opens: 
08/15/2025
Course expires: 
01/05/2026
Event starts: 
12/05/2025 - 7:30am CST
Event ends: 
12/05/2025 - 3:30pm CST
Cost:
$200.00
Add to calendar: 
H O U S T O N    M E T H O D I S T    N E A L    C A N C E R    C E N T E R    
The Annual GI Oncology Summit
Chair: Maen Abdelrahim, MD, PhD, Pharm D
Course Director: Jian Guan, MD
Director, Scientific Planning Committee: Abdullah Esmail, MD
Friday, December 5, 2025 | Hybrid Symposium
TIMEPRESENTATIONSPEAKER(S)
7:30 AMRegistration & Breakfast
7:40 AMPRODUCT THEATRE - Advances in Personalized Molecular Residual Disease Monitoring in GI Cancers
(Presented in Boardroom) *Not certified for CE credit *		Chris Brewer, PhD
8:10 AMWelcome and Leadership Landmark OpeningEdward Jones, MBA
Maen Abdelrahim, MD, PhD, Pharm D
8:30 AMSession 1A: Hepatobiliary Cancer
Session Chair: Mazen Noureddin, MD, MHSc
8:35 AMGlobal Liver Cancer Trends in 2025: Precision Epidemiology and Hepatoprotective StrategiesPierre M. Gholam, MD, FAASLD, AGAF
8:45 AMAI-Powered Hepatocellular Carcinoma Surveillance: Innovations in Risk StratificationNicole Rich, MD, MS
8:55 AMTransforming Pre-Liver Cancer Management: Hepatologist-Led Precision TherapiesJoseph S. Galati, MD
9:05 AMNext-Generation HCC Screening: Liquid Biopsies and Hepatologist-Driven AI ModelsSudha Kodali, MD
9:15 AMPrecision Management of Cirrhosis-Associated HCC: Novel Hepatologist Strategies for 2025Bandar Al-Judaibi, MBBS, MHM, FACP, FRCPC 
9:25 AMPanel DiscussionPierre M. Gholam, MD, FAASLD, AGAF
Nicole Rich, MD, MS
Joseph S. Galati, MD
Sudha Kodali, MD
Bandar Al-Judaibi, MBBS, MHM, FACP, FRCPC
Mazen Noureddin, MD, MHSc
9:40 AMCoffee Break
9:50 AMSession 1B: Hepatobiliary Cancer
Session Chair: Mazen Noureddin, MD, MHSc
9:55 AMNext-Generation Transplant-Bridging Therapies for Hepatocellular CarcinomaMaen Abdelrahim, MD, PhD, Pharm D
10:05 AMImmunotherapy 2.0: Novel Combinations and Biomarkers for HCC in 2025Sukeshi Patel Arora, MD
10:15 AMPrecision Medicine in Cholangiocarcinoma: Targeted Therapies and Immune ModulationMilind Javle, MD
10:25 AMRobotic and Image-Guided Surgery for Early-Stage Hepatobiliary CancersFlavio G. Rocha, MD, FACS, FSSO
10:35 AMTransplant Oncology for Cholangiocarcinoma: Genomic-Guided Strategies for 2025Aiwu Ruth He, MD, PhD
10:45 AMPanel DiscussionMaen Abdelrahim, MD, PhD, Pharm D
Sukeshi Patel Arora, MD
Milind Javle, MD
Flavio G. Rocha, MD, FACS, FSSO
Aiwu Ruth He, MD, PhD
Mazen Noureddin, MD, MHSc
11:00 AMCoffee Break
11:10 AMSession 2: Pancreatic Cancer
Session Chair: Bandar Al-Judaibi, MBBS, MHM, FACP, FRCPC 
11:15 AMTargeted Therapies for Pancreatic Cancer: Biomarker-Driven Advances for 2025Mohammed Alghamdi, MD, MBA
11:25 AMAI-Enabled Early Detection and Risk Stratification for Pancreatic CancerAshish Saharia, MD, FACS
11:35 AMPanel DiscussionMohammed Alghamdi, MD, MBA
Ashish Saharia, MD, FACS
Bandar Al-Judaibi, MBBS, MHM, FACP, FRCPC 
11:45 AMPatient Perspective - Houston Methodist Hospital Jennnifer Hauler, DO, MBA
Kami Walker, JD, BSN
Moderator: Maen Abdelrahim, MD, PhD, PharmD
12:05 PMCoffee Break
12:15 PMSession 3: Colorectal Cancer
Session Chair: Chinemerem Abanonu, MD
12:20 PMPrecision Radiation Oncology for Colorectal Cancer: Adaptive Therapies in 2025Kevin Tran, MD
12:30 PMAdvanced Minimally Invasive Surgery for Colorectal Cancer: 2025 InnovationsJoshua C. Coursey, MD
12:40 PMImmunotherapy Landscape in Colorectal Cancer: What’s New and What’s Next?Fahad Ibnshamsah, MD
12:50 PMGenomic-Driven Precision Oncology in Colorectal Cancer: 2025 Therapeutic FrontiersArvind N. Dasari, MD, MS
1:00 PMImmunotherapy for Colorectal Cancer Beyond MSI-H in 2025Anthony B. El-Khoueiry, MD
1:10 PMAppendiceal Adenocarcinoma: Advances in Diagnosis and Therapeutic Strategies, Are We There Yet?John Paul Y.C. Shen, MD
1:20 PMPanel DiscussionKevin Tran, MD
Joshua C. Coursey, MD
Fahad Ibnshamsah, MD
Arvind N. Dasari, MD, MS
Anthony B. El-Khoueiry, MD
John Paul Y.C. Shen, MD
Chinemerem Abanonu, MD
1:35 PMLUNCH PRODUCT THEATRE - The First and Only Novel Targeted Therapy Approved for mCRC, Regardless of Mutation Status, in More Than a Decade
(Presented in Boardroom) *Not certified for CE credit *		Abhirami Vivekanandarajah, MD, FACP
2:05 PMBreak 
2:15 PMLUNCH PRODUCT THEATRE - Understanding Options in 1L Metastatic Pancreatic Cancer (Presented in Boardroom) *Not certified for CE credit *Michael A. Morse, MD
2:45 PMSession 4: Esophageal and Gastric Cancer
Session Chair: Preethi Prasad, MD
2:50 PMMultidisciplinary Advances in Resectable Gastroesophageal Cancers: Precision Approaches for 2025Anwaar Saeed, MD
3:00 PMImmunotherapy and Biomarker Innovations for Unresectable Gastroesophageal AdenocarcinomaMoh’d Khushman, MD
3:10 PMPrecision Medicine in Gastroesophageal Adenocarcinoma: Novel Targets and Therapies for 2025Monisha Singh, MD
3:20 PMPanel DiscussionAnwaar Saeed, MD
Moh’d Khushman, MD
Monisha Singh, MD
Preethi Prasad, MD
3:30 PMConcluding RemarksMaen Abdelrahim, MD, PhD, Pharm D
Houston Methodist (In-person and virtual attendance options available)
6670 Bertner Avenue
John F. Bookout Auditorium, 2nd Floor
Houston, TX 77030
United States
View Parking Information

LIVE (in-person attendance) will be held in the Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, Texas 77030. 

Virtual information will be provided to registered learners at a later date. 

Available Credit

  • 5.25 AMA PRA Category 1 Credit™

    Houston Methodist is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Houston Methodist designates this Live activity for a maximum of 5.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 5.25 Nursing Contact Hours

    Houston Methodist is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

    Houston Methodist will award up to 5.25 nursing professional development contact hours for this activity.

Interested in exhibiting or sponsoring? Contact us for more information.

Exhibitors

We gratefully acknowledge the following companies for participating as exhibitors for this activity: 

Amgen

Astra Zeneca

Bayer

Bristol Myers Squibb

Exact Sciences

Exelixis

Genentech

Guardant Health

Incyte

Ipsen

Merck

Pfizer

Revolution Medicines

Taiho

Takeda

Tempus

Sponsors

We gratefully acknowledge the following companies for participating as sponsors for this activity: 

Breakfast Sponsor

Boston Scientific

Break Sponsors

Jazz Pharmaceuticals

Tempus

Lunch Sponsor

Exact Sciences

Product Theater Sponsors

Ipsen

Natera

Takeda

 

 

Price

Cost:
$200.00
Please login or register to take this course.

FEES

REGISTRATION TYPEFEE
Houston Methodist EmployeesComplimentary
Physician (Private physician located within the Greater Houston Area)*$200
Physician (Private physician located outside the Greater Houston Area)Complimentary
Research Scientist Complimentary
Allied Health Care Professional / All OthersComplimentary
Resident / Fellow / Student Complimentary

* In compliance with HM’s policy on Physician Non-Monetary Compensation regarding “Stark Law,” private physicians who reside and/or practice medicine within the Greater Houston Area are required to pay the full Fair Market Value registration fee.